Celldex Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
CLDX$31.24+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| (a) | None. |
| (b) | During the three months ended December 31, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5 - 1 trading agreement” or “non - Rule 10b5 - 1 trading agreement,” as each term is defined in Item 408 (a) of Regulation S - K. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.